Search for a trial

Molecular markers in biomaterial derived from patients with inflammatory bowel disease

Systematic gathering of biomaterial and phenotypic data of IBD patients during clinical care provides assessment of molecular markers in the DNA, the transcriptome and proteome. The markers can be associated with the different disease phenotypes…

Less Is More: Optimized pharmacotherapy with improved coNtinuity of CarE in hospitaLized oLder peOple

The LIMONCELLO study aims to assess the effect and cost-effectiveness of TMPC compared to usual care.

Multi-parametric MRI in patients suspected for muscle invasive bladder cancer: a new local staging paradigm

The aim of this study is to determine whether multiparametric MRI (mpMRI) of the bladder, in combination with an outpatient biopsy for histological confirmation, is a faster, safer, cheaper and therefore more cost-effective way to detect or…

The DRAIHA study: Data Registry of AutoImmune Hemolytic Anemia, to improve diagnostic testing for the development of personalized treatment protocols in AIHA patients

Primary objective1. The primary aim of the study is to answer the question whether specification of a positive direct antiglobulin test and/or red blood cell autoantibody specification is correlated with the clinical course in patients with AIHA.…

COMPARISON OF CONVENTIONAL AND COOLED RADIOFREQUENCY TREATMENT OF THE GENICULAR NERVES VERSUS SHAM PROCEDURE FOR PATIENTS WITH CHRONIC KNEE PAIN: A MULTICENTRE, DOUBLE BLIND, RANDOMISED CONTROLLED TRIAL

The aim of the COGENIUS trial is to investigate the effect of the two types of RF treatment on individuals experiencing chronic knee pain that is resistant to conservative treatments. For this purpose, the efficacy and cost-effectiveness of cooled…

Clinical outcomes and cost-effectiveness of a diagnostic and treatment strategy of upfront CTCA plus selective non-invasive functional imaging compared with standard care in patients with chest pain and suspected coronary artery disease

This strategy will result in a reduction reduce the incidence of major adverse cardiovascular events (MACE) defined as death or non-fatal myocardial infarction and appear more efficient than care as usual.